ReviewPharmaceuticals (Basel, Switzerland)2023
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Immune checkpoint inhibitor-induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Observational
- Article
- Immune checkpoint inhibitor-associated scleroderma refractory to corticosteroids: Clinical improvement with intravenous immune globulin and dupilumab.JAAD case reports · 2026Article
- The management of rheumatic immune related adverse events.Best practice & research. Clinical rheumatology · 2026Review
- PD-1 inhibitor-induced systemic sclerosis with early interstitial lung disease and autoimmune thyroiditis in advanced gastric cancer: a case report and literature review.Frontiers in oncology · 2026Article
- Two case reports of eosinophilic fasciitis with onset after immune checkpoint inhibitor cessation.Frontiers in oncology · 2026Article
- Eosinophilic Fasciitis in a 78-Year-Old Man Following Pembrolizumab Treatment for Bladder Cancer.The American journal of case reports · 2025Article
- Mechanisms of autoimmune-mediated paraneoplastic syndromes: immune tolerance and disease pathogenesis.Frontiers in immunology · 2025Review
- Muscle weakness, myositis and scleroderma induced by durvalumab.Respirology case reports · 2024Article
- Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.Expert review of clinical immunology · 2024Review
- Scleroderma-like Lesions in a Patient Undergoing Combined Pembrolizumab and Routine Chemotherapy: A Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database.Drugs - real world outcomes · 2024Article
- Immune Checkpoint Inhibitor-Associated Systemic Sclerosis in the Treatment of a Small Cell Lung Cancer Patient with Durvalumab: A Case Report.Clinical, cosmetic and investigational dermatology · 2024Article
- Biomarkers in Systemic Sclerosis: An Overview.Current issues in molecular biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICI) are the standard of care for various malignancies and have been associated with a wide spectrum of complications that are phenotypically akin to primary autoimmune diseases. While the literature on these toxicities is growing, there is a paucity of data regarding ICI-associated scleroderma which can carry significant morbidity and limit the ability to continue effective ICI therapy. Our review aimed to analyze the current literature on ICI-associated systemic scleroderma (ICI-SSc) and key scleroderma mimics. Cases of ICI-SSc had notable differences from primary SSc, such as fewer vascular features and less seropositivity (such as scleroderma-specific antibodies and antinuclear antibodies). We found that patients with a diagnosis of SSc prior to the start of ICI can also experience flares of pre-existing disease after ICI treatment used for their cancer. Regarding scleroderma mimics, several cases of ICI-eosinophilic fasciitis have also been described with variable clinical presentations and courses. We found no cases of scleroderma mimics: ICI-scleromyxedema or ICI-scleroedema. There is a critical need for multi-institutional efforts to collaborate on developing a patient database and conducting robust, prospective research on ICI-scleroderma. This will ultimately facilitate more effective clinical evaluations and management for ICI-scleroderma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.